Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy Daniel L. Hertz The Pharmacogenomics Journal 2019 19 :411 - 416; August 09, 2019; 10.1038/s41397-019-0093-1 Abstract | Full Text
ARTICLE
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients Sarah Allegra, Jessica Cusato, Silvia De Francia, Filomena Longo, Elisa Pirro et al. The Pharmacogenomics Journal 2019 19 :417 - 427; January 17, 2019; 10.1038/s41397-019-0071-7 Abstract | Full Text
Prognostic role of genetic polymorphisms of the interleukin-6 signaling pathway in patients with severe heart failure Peter R. Hansen, Karl Emil Nelveg-Kristensen, Henrik B. Rasmussen, Christian Torp-Pedersen, Lars Køber et al. The Pharmacogenomics Journal 2019 19 :428 - 437; January 17, 2019; 10.1038/s41397-019-0068-2 Abstract | Full Text
Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention Vasilios Fragoulakis, Marina Bartsakoulia, Xando Díaz-Villamarín, Konstantina Chalikiopoulou, Konstantina Kehagia et al. The Pharmacogenomics Journal 2019 19 :438 - 445; January 16, 2019; 10.1038/s41397-019-0069-1 Abstract | Full Text
Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients – a randomized, prospective study Tereza Ruzickova, Martin Sramek, Vojtech Kaplan, Simona Kumstyrova, Zuzana Lacinova et al. The Pharmacogenomics Journal 2019 19 :446 - 454; January 16, 2019; 10.1038/s41397-019-0066-4 Abstract | Full Text
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib Marta Schirripa, Beatrice Borelli, Romina D’Aurizio, Simone Lubrano, Chiara Cremolini et al. The Pharmacogenomics Journal 2019 19 :455 - 464; January 28, 2019; 10.1038/s41397-019-0075-3 Abstract | Full Text
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? Federico Nichetti, Felicia Stefania Falvella, Rosalba Miceli, Stefania Cheli, Raffaella Gaetano et al. The Pharmacogenomics Journal 2019 19 :465 - 472; February 04, 2019; 10.1038/s41397-019-0078-0 Abstract | Full Text
Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors Michiel C. Verboom, Jacqueline S. L. Kloth, Jesse J. Swen, Stefan Sleijfer, Anna K. L. Reyners et al. The Pharmacogenomics Journal 2019 19 :473 - 479; February 04, 2019; 10.1038/s41397-019-0079-z Abstract | Full Text
An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care Reinier L. Sluiter, Joost G. E. Janzing, Gert Jan van der Wilt, Wietske Kievit & Martina Teichert The Pharmacogenomics Journal 2019 19 :480 - 489; January 16, 2019; 10.1038/s41397-019-0070-8 Abstract | Full Text
CONSENSUS STATEMENT
Association between SOST gene polymorphisms and response to alendronate treatment in postmenopausal Chinese women with low bone mineral density W.-J. Wang, W.-Z. Fu, J.-W. He, C. Wang & Z.-L. Zhang The Pharmacogenomics Journal 2018 19 :490 - 498; October 05, 2018; 10.1038/s41397-018-0059-8 Abstract | Full Text